<DOC>
	<DOCNO>NCT01661270</DOCNO>
	<brief_summary>Primary Objective : To evaluate improvement progression-free survival ( PFS ) aflibercept versus placebo participant metastatic colorectal cancer treat FOLFIRI second-line treatment metastatic disease . Secondary Objectives : To compare overall survival ( OS ) 2 treatment arm . To compare overall response rate ( ORR ) 2 treatment arm . To assess safety profile 2 treatment arm . To assess immunogenicity intravenous ( IV ) aflibercept select center .</brief_summary>
	<brief_title>A Study Aflibercept Versus Placebo With FOLFIRI Patients With Metastatic Colorectal Cancer Previously Treated With Oxaliplatin Chemotherapy</brief_title>
	<detailed_description>Screening occur sign inform consent randomization ( 21 day ) . A treatment cycle define 2 week-period . All participant follow study treatment follow-up period death study cut date , ever come first .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Inclusion criterion : Histological cytological proven adenocarcinoma colon rectum . Metastatic disease amenable potentially curative treatment . One one prior chemotherapeutic regimen metastatic disease . This prior chemotherapy must oxaliplatin contain regimen . Participants relapse within 6 month completion oxaliplatin base adjuvant chemotherapy eligible . Exclusion criterion : Prior therapy irinotecan . Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 1 . Less 28 day elapse prior radiotherapy , prior surgery prior chemotherapy time randomization . Less 42 day elapse prior major surgery time randomization . Adverse event ( exception alopecia , peripheral sensory neuropathy grade â‰¤ 2 list specific exclusion criterion ) prior anticancer therapy grade &gt; 1 ( National Cancer Institute Common terminology Criteria [ NCI CTCAE ] v.3.0 ) time randomization . Age &lt; 18 year . History brain metastasis , uncontrolled spinal cord compression , carcinomatous meningitis new evidence brain leptomeningeal disease . Other prior malignancy . Adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix cancer participant disease free &gt; 5 year allow . Participation another clinical trial investigational drug concurrent treatment investigational drug within 30 day prior randomization . Any follow within 6 month prior randomization : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , New York Heart Association Functional Classification ( NYHA ) class III IV congestive heart failure , stroke transient ischemic attack . Any follow within 3 month prior randomization : treatment resistant peptic duodenal ulcer disease , erosive oesophagitis gastritis , grade 3 4 gastrointestinal bleeding/hemorrhage , gastrointestinal perforation/fistula , abdominal abscess , infectious inflammatory bowel disease , diverticulitis , pulmonary embolism , uncontrolled thromboembolic event . Participants give high dose aspirin non steroidal antiinflammatory agent ( NSAIDS ) high steroid within 4 week prior randomization . The definition `` high dose '' base investigator 's judgment . Occurrence deep vein thrombosis within 4 week , prior randomization . Inadequate organ bone marrow function . Pregnant breastfeed woman . Positive serum urine pregnancy test prior randomization . Participants reproductive ( M/F ) agree use accept effective method contraception study treatment period least 6 month follow completion study treatment . Uncontrolled hypertension . Urine Protein : creatine ratio ( UPCR ) &gt; 1 morning spot urinalysis proteinuria &gt; 500mg/24 hour . Participants anticoagulant therapy unstable dose warfarin and/or outoftherapeutic range international normalize ratio ( INR ) ( &gt; 3 ) within 4 week prior randomization . Evidence clinically significant bleed diathesis underlie coagulopathy . Known dihydropyrimidine dehydrogenase deficiency . Predisposing colonic small bowel disorder symptom uncontrolled indicated baseline &gt; 3 loose stool daily . Prior history chronic enteropathy , inflammatory enteropathy , chronic diarrhea , unresolved bowel obstruction/subobstruction , hemicolectomy , extensive small intestine resection chronic diarrhea . History anaphylaxis know intolerance atropine sulphate loperamide appropriate antiemetic administer conjunction FOLFIRI . Treatment concomitant anticonvulsant agent cytochrome P450 3A4 ( CYP3A4 ) inducer ( phenytoin , phenobarbital , carbamazepine ) , unless discontinue &gt; 7 day . Participants know Gilbert 's syndrome . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>